Google
ARGX Stock Analysis — ARGENX NV ADR (Healthcare >> Biotechnology)
ARGX FAQ
What is ARGX's P/E ratio?
ARGENX NV ADR (ARGX) currently trades at a P/E ratio of 21.03.
What is ARGX's ROE?
ARGENX NV ADR reports a Return on Equity (ROE) of 30.84%.
What is ARGX's dividend yield?
ARGENX NV ADR offers a dividend yield of 0.00%.
What is ARGX's Quality Score?
Our AI rates ARGX's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy ARGX?
Our AI Timing Score for ARGX is 71 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does ARGX belong to?
ARGENX NV ADR is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
ARGX AI Analysis Summary
Our AI summary for ARGX: ARGENX NV ADR (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 21.03, ROE of 30.84%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 71/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 853.82
Price
-18.76
(-2.15%)
Day Change
|
|
|---|
ARGX, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
701
|
| Magic Formula Rank by ROE |
701
|
| Magic Formula Rank by ROIC |
622
|
| Price | 853.82 |
| PBV / Sector |
6.49 / 5.20
|
| Earning Per Share | 40.60 |
| PE / Sector |
21.03 / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
253.24 M
GREAT
|
| Average 1W Daily Value |
231.19 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:29 |
| Symbol | ARGX |
| Name | ARGENX NV ADR |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 62.56 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 54,589.47 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Laarderhoogtweg 25, Amsterdam, Netherlands, 1101 EB
Phone: 31 10 703 8441
Website: https://argenx.com
Employees: 1,863
Sector: Healthcare >> Biotechnology
Description: argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap